Ruth Villanueva

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice

O. Vasiljeva, G. V. van Dongen, D. Vugts, 2020, Theranostics.

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration

F. Gizatullin, T. Ghayur, Kangwen Deng, 2018, mAbs.

The use of cyclic peptide antigens to generate LRP8 specific antibodies

D. Egan, F. Gizatullin, J. Harlan, 2023, Frontiers in Drug Discovery.